UPTIDE
Pathway

GHRH Signalling

GHRH analogues bind pituitary GHRH receptors to drive pulsatile GH release; DAC technology extends half-life through albumin binding.

Diagram

GHRH analogueligandGHRH-RreceptorSomatotropheffectorGH pulseoutcome

Related compounds

Investigated in the context of this pathway

CJC-1295 with DAC — Uptide research-grade vial
Limited Human

CJC-1295 with DAC

3647.2 g/mol

Long-acting GHRH analog

Endocrine
CJC-1295 without DAC — Uptide research-grade vial
Limited Human

CJC-1295 without DAC

3367.95 g/mol

Short-acting GHRH analog

Endocrine
Sermorelin — Uptide research-grade vial
Human Clinical

Sermorelin

3357.93 g/mol

Synthetic GHRH analog

Endocrine
Tesamorelin — Uptide research-grade vial
Human Clinical

Tesamorelin

5135.79 g/mol

Synthetic GHRH analog

EndocrineMetabolic
home